3/31
07:44 am
ptn
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study [Yahoo! Finance]
Medium
Report
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study [Yahoo! Finance]
3/31
07:30 am
ptn
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
High
Report
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
3/28
07:30 am
ptn
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
High
Report
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
3/25
07:56 am
ptn
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency [Yahoo! Finance]
High
Report
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency [Yahoo! Finance]
3/25
07:30 am
ptn
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
High
Report
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
2/13
08:09 am
ptn
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
2/13
07:30 am
ptn
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Medium
Report
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
2/10
04:00 pm
ptn
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Medium
Report
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
2/7
08:34 am
ptn
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]
Medium
Report
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]
2/7
08:13 am
ptn
Palatin Technologies prices 4.69M shares in direct offering [Seeking Alpha]
High
Report
Palatin Technologies prices 4.69M shares in direct offering [Seeking Alpha]
2/7
08:00 am
ptn
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Low
Report
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
2/6
08:17 am
ptn
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide [Yahoo! Finance]
High
Report
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide [Yahoo! Finance]
2/6
07:30 am
ptn
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
High
Report
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
1/28
07:30 am
ptn
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Low
Report
Palatin Provides Update on Anticipated 2025 Corporate Milestones